R-MDMA

Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies

Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options.

Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment

Biopharma company Atai Life Sciences (NASDAQ: ATAI) shared positive results from a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, under development for the potential treatment of PTSD.